Article Text

other Versions

PDF
Review
Propranolol for infantile haemangiomas: a review
  1. E Starkey,
  2. H Shahidullah
  1. Derbyshire Children's Hospital, Derby, UK
  1. Correspondence to E Starkey, Derbyshire Children's Hospital, Uttoxeter Road, Derby DE22 3NE, UK; elizabeth.starkey{at}nhs.net

Abstract

Infantile haemangiomas are the most common benign tumour of infancy. However the majority are self-resolving and only a small minority of cases require treatment, with various different medications being used in the past. Over the last few years, propranolol, a non-selective β-blocker, has become a popular and successful treatment for infantile haemangiomas. However, further research on its safety is needed if it is going to be used more frequently. This article summarises the current literature on propranolol for haemangioma treatment with emphasis on its toxicity and adverse event profile.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.